Acute Myeloid Leukemia (AML)

VENCLEXTA Fact Sheet

Venclexta® (also known as Venetoclax) is a prescribed oral tablet approved by the Food and Drug Administration for adult patients with acute myeloid leukemia (AML)

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia

Original Publication Date
Article Source
External Web Content
Highlights Heme biosynthesis enzymes are variably suppressed in AML Heme levels are linked with altered leukemic transcriptional programs via BACH1 Heme biosynthesis is a selective dependency in AML, both in vitro and in vivo Heme starvation disrupts complex IV, inducing copper…

Instructions

Not all healthcare professionals or emergency responders will understand your rare diagnosis and unique needs. AAMDSIF has created an emergency health information card that communicates to others what they need to know…

10th International Bone Marrow Failure Disease Scientific Symposium

Thumbnail for video Register Now

Topic(s)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
The 10th International Bone Marrow Failure Disease Scientific Symposium will convene physicians, laboratory researchers and clinical investigators to discuss current areas of consensus and controversy, share recent research results, and clarify promising directions for…

ASH 2021 MDS and AML - for Patients

This publication offers summaries of selected abstracts presented at the December 2021 Meeting of the American Hematology Society. It provides new and updated information about new research into the diagnosis, treatment…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.